Multivalent mannose-conjugated siRNA causes robust gene silencing in pancreatic macrophages in vivo
European Journal of Pharmaceutics and Biopharmaceutics · 2023
DOI: 10.1016/j.ejpb.2022.12.017 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Pharmaceutics and Biopharmaceutics, 2023. Verfasst von Kazuto Yamazaki und 7 weiteren Autor:innen. Beteiligte Einrichtung: Tsukuba Research Laboratories, Eisai Co., Ltd., 5-1-3, Tokodai, Tsukuba, Ibaraki 300-2635, Japan. Electronic address: k5-yamazaki@hhc.eisai.co.jp. Hauptthemen laut MEDLINE: Mannose, Macrophages. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: Eisai Canada.
Abstract (Originalsprache)
Nucleic acid therapeutics have been utilized for gene regulation, and their recent advancement has led to approval of novel drugs for liver-related disorders. However, systemic extrahepatic delivery remains challenging. Here, we report newly designed mannose-conjugated oligonucleotides for delivering oligonucleotides to macrophages by leveraging the mannose receptor, C-type 1 (MRC1, CD206), which is abundantly expressed in macrophages. We investigated the relationship between cellular uptake and multivalency (mono to tetra) of mannose ligands or linker length and selected a trivalent-mannose ligand. Trivalent-mannose (Man3)-conjugated siRNA induced concentration-dependent gene silencing in both human CD206-overexpressing cells and human macrophages in vitro. After subcutaneous injection into mice, we observed a high distribution of Man3-conjugated oligonucleotides in the liver and pancreata as well as cellular uptake into Kupffer cells and pancreatic macrophages. A single subcutaneous injection of Man3-conjugated siRNA (10 mg/kg) targeting β2-microglobulin (B2M) silenced B2m mRNA expression by ∼50% and decreased its protein levels in mouse pancreatic macrophages compared to those in saline-treated mice. Of note, multiple subcutaneous injections decreased B2m gene expression and B2M protein levels by ∼80% and ∼85%, respectively. These results show that mannose-conjugation with oligonucleotides is expected to help deliver oligonucleotides to macrophages and regulate gene expression in vivo, particularly in the pancreas.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Tsukuba Research Laboratories, Eisai Co., Ltd., 5-1-3, Tokodai, Tsukuba, Ibaraki 300-2635, Japan. Electronic address: k5-yamazaki@hhc.eisai.co.jp.
- Tsukuba Research Laboratories, Eisai Co., Ltd., 5-1-3, Tokodai, Tsukuba, Ibaraki 300-2635, Japan.
- Department of Immunology, Yokohama City University Graduate School of Medicine, 3-9, Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan.
Förderung
- Eisai Canada
Zitieren
APA
Yamazaki, K., Kubara, K., Suzuki, Y., Hihara, T., Kurotaki, D., Tamura, T., Ito, M., & Tsukahara, K. (2023). Multivalent mannose-conjugated siRNA causes robust gene silencing in pancreatic macrophages in vivo. European Journal of Pharmaceutics and Biopharmaceutics. https://doi.org/10.1016/j.ejpb.2022.12.017
Vancouver
Yamazaki K, Kubara K, Suzuki Y, Hihara T, Kurotaki D, Tamura T, et al. Multivalent mannose-conjugated siRNA causes robust gene silencing in pancreatic macrophages in vivo. European Journal of Pharmaceutics and Biopharmaceutics. 2023. doi:10.1016/j.ejpb.2022.12.017
BibTeX
@article{Yamazaki2023,
author = {Yamazaki, Kazuto and Kubara, Kenji and Suzuki, Yuta and Hihara, Taro and Kurotaki, Daisuke and Tamura, Tomohiko and Ito, Masashi and Tsukahara, Kappei},
title = {Multivalent mannose-conjugated siRNA causes robust gene silencing in pancreatic macrophages in vivo},
journal = {European Journal of Pharmaceutics and Biopharmaceutics},
year = {2023},
doi = {10.1016/j.ejpb.2022.12.017}
}
EUVIMED